|
Re: Tick tock
|
3
|
Resverlogix Corp.
|
Dec 13, 2018 07:00AM
|
|
December Corporate Presentation
|
4
|
BIOASIS TECHNOLOGIES INC
|
Dec 13, 2018 10:10AM
|
|
No love
|
3
|
Resverlogix Corp.
|
Dec 13, 2018 12:08PM
|
|
Re: No love
|
4
|
Resverlogix Corp.
|
Dec 13, 2018 12:23PM
|
|
Re: No love
|
4
|
Resverlogix Corp.
|
Dec 13, 2018 12:46PM
|
|
Re: No love
|
3
|
Resverlogix Corp.
|
Dec 13, 2018 12:55PM
|
|
Re: No love
|
5
|
Resverlogix Corp.
|
Dec 13, 2018 02:35PM
|
|
Re: Tick tock
|
5
|
Resverlogix Corp.
|
Dec 13, 2018 10:31PM
|
|
Re: Two Thoughts - 250 and 270
|
1
|
Resverlogix Corp.
|
Dec 14, 2018 09:24AM
|
|
Re: Two Thoughts - 250 and 270
|
4
|
Resverlogix Corp.
|
Dec 14, 2018 11:13AM
|
|
Re: Slides up for "LDL-C: DONE DEAL, NEXT EPIGENETICS?" Symposium
|
5
|
Resverlogix Corp.
|
Dec 14, 2018 01:01PM
|
|
ERA-EDTA 2018 Symposium Presentations "Epigenetics in CKD & CVD: A potential breakthrough therapy?"
|
1
|
Resverlogix Corp.
|
Dec 14, 2018 01:32PM
|
|
Re: MD&A out
|
3
|
Resverlogix Corp.
|
Dec 14, 2018 02:26PM
|
|
Re: CANTOS good, but FDA not on board with sub-group analysis
|
4
|
Resverlogix Corp.
|
Dec 14, 2018 03:17PM
|
|
Re: MD&A out
|
1
|
Resverlogix Corp.
|
Dec 14, 2018 10:58PM
|
|
Re: MD&A out
|
1
|
Resverlogix Corp.
|
Dec 15, 2018 10:25AM
|
|
Re: MD&A out
|
2
|
Resverlogix Corp.
|
Dec 15, 2018 04:35PM
|
|
A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Dec 17, 2018 10:02AM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
3
|
Resverlogix Corp.
|
Dec 17, 2018 11:52AM
|
|
Re: 2019 Potential Events
|
1
|
Resverlogix Corp.
|
Dec 17, 2018 12:23PM
|
